Small RNA sequencing reveals a comprehensive miRNA signature of<i>BRCA1</i>-associated high-grade serous ovarian cancer

Brouwer, Jan; Kluiver, Joost; Almeida, Rodrigo Coutinho de; Modderman, Rutger; Terpstra, Miente Martijn; Kok, Klaas; Withoff, Sebo; Hollema, Harry; Reitsma, Welmoed; Bock, Geertruida H. de; Mourits, Marian J.E.; Berg, Anke van den

doi:10.1136/jclinpath-2016-203679

Cited by 11 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing the lack of respective data in ovarian cancer and owing the fact that BBC and HGSOC share striking similarities regarding molecular and genetic profiles [10,11], i.e. that N90% of BBC carry TP53 mutations, which is also a hallmark in HGSOC [1], that frequencies of RB1 and CMYC pathway mutations are also significantly similar in BBC and HGSOC [11,12], that transcriptomic profiles are shared by both cancer types [13,14] and that BRCA1/2 mutations are frequently found in BBC [12] and HGSOC [15][16][17], we investigated the putative role of MELK in EOC.…”

Section: Introductionmentioning

confidence: 99%

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells

Kohler

Kettelhack

Knipprath-Mészáros

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells

Kohler

Kettelhack

Knipprath-Mészáros

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Based on miRNA microarray data obtained from analysis on normal ovarian surface epithelium and ovarian tumors, Shahab and coworkers identified forty-two miRNAs, out of which thirty-three were over-expressed and nine miRNAs were down-regulated in OC [9]. In a recent study, small RNA sequencing was performed on normal tubal and high-grade serous ovarian cancer samples leading to identification of differential expression of several miRNAs, of which 59 were known and 20 were novel [10]. Another recent study identified 1156 deregulated miRNAs in OC [11].…”

Section: Dysregulation Of Mirnas In Gynecologic Cancersmentioning

confidence: 99%

“…From the plasma of patients with OC, a specific miRNA signature was detected. This included nineteen down-regulated and three over-expressed miRNAs in OC patients, as compared to plasma of controls [10]. Moreover, six miRNAs, miR-126, miR-150, miR-17, miR-20a, miR-106b, and miR-92a, were efficient enough to distinguish benign plasma from that of sample of OC patients.…”

Section: Dysregulation Of Mirnas In Gynecologic Cancersmentioning

confidence: 99%

MicroRNAs in gynecological cancers: Small molecules with big implications

et al. 2017

View full text Add to dashboard Cite

Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy of available therapeutic options. Thus, there remains an urgent and unmet need for innovative research for the efficient clinical management of GC patients. Research over past several years has revealed the enormous promise of miRNAs. These small non-coding RNAs can aid in the diagnosis, prognosis and therapy of all major GCs, viz., ovarian cancers, cervical cancers and endometrial cancers. Mechanistic details of the miRNAs-mediated regulation of multiple biological functions are under constant investigation, and a number of miRNAs are now believed to influence growth, proliferation, invasion, metastasis, chemoresistance and the relapse of different GCs. Modulation of tumor microenvironment by miRNAs can possibly explain some of their reported biological effects. miRNA signatures have been proposed as biomarkers for the early detection of GCs, even the various subtypes of individual GCs. miRNA signatures are also being pursued as predictors of response to therapies. This review catalogs the knowledge gained from collective studies, so as to assess the progress made so far. It is time to ponder over the knowledge gained, so that more meaningful pre-clinical and translational studies can be designed to better realize the potential that miRNAs have to offer.

show abstract

“…These differentially expressed miRNAs may serve as diagnostic biomarkers for ovarian cancer in association with endometriosis. More recently, 59 known and 20 novel miRNAs were found to be differentially expressed between normal tubal tissue and BRCA1-assoicated high-grade serous ovarian carcinoma [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma

et al. 2018

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have recently demonstrated great potential and enormous promise in the diagnosis, prognosis and therapy of various types of cancer. In this study, we performed a comprehensive miRNA expression analysis in the omental metastasis of serous ovarian carcinoma (SOC) using small RNA sequencing. Two hundred and fifty-one aberrantly expressed miRNAs were identified, which clearly separated malignant omentum from normal omentum. Furthermore, miRNA profiles in primary chemo-sensitive and chemo-resistant/refractory SOC were determined using publicly available data. Comparing miRNA expression profiles in omental metastases and primary chemo-sensitive and chemo-resistant/refractory tumors, a set of 70 miRNAs that were aberrantly expressed in both primary and metastatic SOC has been identified for the first time. These core aberrantly expressed miRNAs may play crucial roles in the tumorigenesis, growth, and metastasis of SOC. Therefore, they can serve as potential diagnostic biomarkers and as therapeutic targets for miRNA-mediated therapy. Kaplan–Meier overall survival analysis using The Cancer Genome Atlas data demonstrated that 10 miRNAs (hsa-miR-135, 150, -340, 625, 1908, 3187, -96, -196b, -449c, and -1275) were associated with survival of patients with SOC, which may serve as potential prognostic biomarkers.

show abstract

Small RNA sequencing reveals a comprehensive miRNA signature ofBRCA1-associated high-grade serous ovarian cancer

Cited by 11 publications

References 30 publications

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells

MicroRNAs in gynecological cancers: Small molecules with big implications

Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma

Contact Info

Product

Resources

About